Yan Ji

Novartis Pharmaceuticals Corp

United States

Research Interests

Explore related searches

Professors in United States

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (1)

Bart Hendriks

Novartis Institutes for BioMedical Research Inc

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yan Ji

Research Interests

Explore related searches

Articles (11)

Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria

Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer

Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System

Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.

Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis

A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome

Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials

Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment

Collaborators (1)

Bart Hendriks

Make your next move.